PMID- 30451173
OWN - NLM
STAT- MEDLINE
DCOM- 20190208
LR  - 20190215
IS  - 1998-3689 (Electronic)
IS  - 0301-4738 (Print)
IS  - 0301-4738 (Linking)
VI  - 66
IP  - 12
DP  - 2018 Dec
TI  - Current management strategy of polypoidal choroidal vasculopathy.
PG  - 1727-1735
LID - 10.4103/ijo.IJO_975_18 [doi]
AB  - Polypoidal choroidal vasculopathy (PCV) is a retinal disorder commonly found in 
      Asians presenting as neovascular age-related macular degeneration and is 
      characterized by serous macular detachment, serous or hemorrhagic pigment 
      epithelial detachment, subretinal hemorrhage, and occasionally visible orange-red 
      subretinal nodular lesions. PCV is diagnosed using indocyanine green angiography 
      (ICGA), and the lesions appear as polypoidal aneurysmal vascular lesions with or 
      without abnormal branching vascular network. Although ICGA remains the gold 
      standard for the diagnosis of PCV, various imaging modalities have also 
      facilitated the diagnosis and monitoring of PCV. Recent advances in imaging 
      technology including the use of high resolution spectral domain optical coherence 
      tomography (OCT) and OCT angiography have provided new insights on the 
      pathogenesis of PCV, suggesting a link between PCV and pachychoroid spectrum of 
      macular disorders. With the evolving understanding on the pathogenesis and 
      clinical characteristics of PCV, different therapeutic options have been 
      proposed. These include intravitreal anti-vascular endothelial growth factor 
      (anti-VEGF) monotherapy, combination therapy with anti-VEGF and verteporfin 
      photodynamic therapy, and thermal laser photocoagulation. In recent years, major 
      multi-center randomized clinical trials such as EVEREST, EVEREST II, and PLANET 
      studies have been conducted to compare the efficacy and safety of various 
      treatment options for PCV. This review aims to summarize the results of recent 
      literature, clinical trials and studies to provide an update on the management 
      options of PCV. An overall management strategy for PCV will also be proposed.
FAU - Ho, Christine P S
AU  - Ho CPS
AD  - Faculty of Medicine, The University of Hong Kong; 2010 Retina and Macula Centre, 
      Kowloon, Hong Kong SAR.
FAU - Lai, Timothy Y Y
AU  - Lai TYY
AD  - Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, The 
      Chinese University of Hong Kong; 2010 Retina and Macula Centre, Kowloon, Hong 
      Kong SAR.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Indian J Ophthalmol
JT  - Indian journal of ophthalmology
JID - 0405376
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Angiogenesis Inhibitors/*administration & dosage
MH  - Choroid/*blood supply
MH  - Choroid Diseases/*diagnosis/drug therapy
MH  - Disease Management
MH  - Fluorescein Angiography/*methods
MH  - Fundus Oculi
MH  - Humans
MH  - Intravitreal Injections
MH  - Photochemotherapy/*methods
MH  - Polyps/*diagnosis/drug therapy
MH  - Tomography, Optical Coherence/*methods
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
PMC - PMC6256896
OTO - NOTNLM
OT  - Anti-VEGF therapy
OT  - neovascular age-related macular degeneration
OT  - photodynamic therapy
OT  - polypoidal choroidal vasculopathy
COIS- There are no conflicts of interest
EDAT- 2018/11/20 06:00
MHDA- 2019/02/09 06:00
PMCR- 2018/12/01
CRDT- 2018/11/20 06:00
PHST- 2018/11/20 06:00 [entrez]
PHST- 2018/11/20 06:00 [pubmed]
PHST- 2019/02/09 06:00 [medline]
PHST- 2018/12/01 00:00 [pmc-release]
AID - IndianJOphthalmol_2018_66_12_1727_245646 [pii]
AID - IJO-66-1727 [pii]
AID - 10.4103/ijo.IJO_975_18 [doi]
PST - ppublish
SO  - Indian J Ophthalmol. 2018 Dec;66(12):1727-1735. doi: 10.4103/ijo.IJO_975_18.